(MENAFN- GlobeNewsWire - Nasdaq) Argentina's diabetes devices market experiences robust advancement, bolstered by youth-specific solutions, smart sensors, and solid distribution alliances. Indonesia's automotive financing accelerates amid surging consumer aspirations, resilient credit systems, and rapidly evolving digital loan platforms, fueling a remarkable dual-market trajectory.New Delhi, Jan. 01, 2025 (GLOBE NEWSWIRE) -- According to the latest study from Astute Analytica, the Argentina diabetes devices market is projected to hit the market valuation of US$ 1,031.89 million by 2033 from US$ 539.12 million in 2024 at a CAGR of 7.48% during the forecast period 2025–2033.
Argentina has emerged as a pivotal market for innovative diabetes devices, driven by rising awareness campaigns and ongoing medical advancements. According to the Argentine Society of Diabetes, 47% of diabetes patients in the country reported heightened interest in next-generation glucose monitors in 2024, reflecting a notable shift from conventional testing methods. In the same period, 38% of endocrinologists in Buenos Aires recommended continuous glucose monitoring (CGM) systems for type 2 diabetes management, highlighting evolving treatment protocols. The Ministry of Health revealed that 69% of diabetes-related hospital admissions in 2023 were linked to insufficient glycemic control, emphasizing an urgent need for accessible monitoring tools. Moreover, 41% of healthcare facilities in larger provinces adopted telemedicine platforms to enhance patient access to their device data.
Download Sample Copy @
Within Argentina's public hospitals, 57% of diabetes patients surveyed in 2024 expressed a desire for more insurance coverage of advanced insulin pumps. Meanwhile, 22% of Argentinians in the diabetes devices market with newly diagnosed diabetes began using digital health apps in 2023 to track vital metrics, illustrating the population's growing acceptance of tech-driven solutions. The National Observatory of Chronic Diseases noted that 66% of individuals who utilize modern glucometers experienced fewer diabetic complications, demonstrating significant clinical benefits. During 2023, 74% of private clinics in Córdoba reported leveraging remote consultation platforms to support device training, underscoring the healthcare sector's readiness to evolve. Furthermore, 49% of medical practitioners in mid-sized Argentinian cities advocated for integrated diabetes device ecosystems, reflecting the market's untapped potential for cohesive, data-driven care solutions.
Key Findings in Argentina Diabetes Devices Market
| Market Forecast (2033) | US$ 1,031.89 million |
| CAGR | 7.48% |
| By Types | Blood Glucose Meters and Strips (48.43%) |
| By Diabetes Type | Type 2 (45.15%) |
| By End Users | Self & Homecare (60.31%) |
| By Demography | Adults (65.25%) |
| By Sales Channel | Retail Pharmacies (38.31%) |
| Top Drivers | Accelerating prevalence of youth diabetes demanding advanced monitoring and treatment solutions Expanding rural healthcare programs unlocking affordable diabetes device accessibility nationwide Rising telehealth collaborations ensuring timely diabetes self-management support and guidance |
| Top Trends | Integrating wearable sensors empowering proactive real-time glucose data tracking Adopting AI-driven meal planning influencing personalized insulin dosing strategies Collaborating with pharmacies facilitating convenient in-store diagnostic device availability |
| Top Challenges | Maintaining supply chains amid fluctuating exchange rates constraining procurement capacities Ensuring local technical expertise tackling complex device software interoperability issues Addressing cultural barriers discouraging consistent digital health tool usage adoption |
Dominance Among Key Device Categories: Pens, Pumps, Meters, Monitors, and More
Insulin pens, insulin pumps, self-monitoring blood glucose (SMBG) meters, and continuous glucose monitors (CGMs) have each carved out strong positions within Argentina's diabetes devices market landscape. Recent data from a 2024 clinical audit suggests that continuous glucose monitor and strip along with insulin pens lead in popularity, with 52% of newly prescribed insulin therapies leveraging pen-based delivery systems. Meanwhile, insulin pumps, though traditionally limited to advanced centers, are growing in acceptance, with a notable 23% rise in prescriptions among type 1 patients over the last 12 months. CGMs are increasingly favored, as 29% of individuals living with diabetes now rely on sensor-based glucose readings for real-time insights. Additionally, SMBG meters remain a foundational tool, as 81% of diabetes patients continue using these meters at least twice daily.
Among younger adults under 40, 42% survey individuals in the diabetes devices market reported preferring wearable technologies for glucose control, indicating a lean toward CGM patches equipped with smartphone connectivity. A 2023 survey noted that 35% of Argentinian pharmacists observed a growing demand for sensor-enabled devices, underlining an evolving consumer shift. Insulin patch pumps, though still relatively niche, saw a 14% increase in availability in private hospitals across the country. Across both urban and semi-urban clinics, 68% of endocrinologists now advocate a combined approach-using SMBG meters for baseline readings alongside periodic CGM usage. Furthermore, 27% of public health programs in 2024 introduced educational initiatives on selecting appropriate insulin delivery systems. Finally, 53% of diabetes specialists emphasize the multi-device approach, noting that diversified options drive better glycemic management and reduce hospital revisits.
Demographic Analysis: Diverse Age, Gender, Income Impact Device Usage Patterns in Argentina Diabetes Devices Market
Argentina's demography plays a decisive role in shaping diabetes device market growth and adoption. Currently, adults are the largest consumers of the these devices. In 2023, a study from the National Institute of Statistics and Censuses indicated that 33% of individuals aged 60 and above with diabetes in urban centers rely on CGMs, whereas only 18% within the same age bracket in rural areas use similar technology. Among low-income communities, 48% of respondents cited cost as the major barrier to insulin pump adoption, while 59% in higher-income brackets felt confident about covering out-of-pocket device expenses. Furthermore, 21% of women under 35 with gestational diabetes reported significant reliance on smartphone-compatible glucometers for daily monitoring. Meanwhile, 61% of men with prediabetes across various age groups expressed interest in wearable glucose trackers for preventive oversight.
Gender differences extend into device usage frequency: 54% of women with type 2 diabetes in Buenos Aires tested their blood glucose at least three times weekly, compared to 43% of men following the same protocol. In 2024, government-led programs in five provinces of the Argentina diabetes devices market introduced subsidized test strips for individuals over 55, benefiting nearly 25% of lower-income diabetes patients in those regions. Overall, 63% of younger adults aged 20–29 reported confidence in using app-linked devices, underscoring strong digital literacy. Another key insight shows that 29% of high-income families in metropolitan areas combined multiple devices-like insulin pens and sensor patches-to tackle varied glycemic patterns. Finally, 36% of rural diabetes support groups collaborated with telemedicine platforms to empower local patients, reflecting an inclusive push toward broader device availability.
Diabetes Type Dominance: Differentiating Preferences In Type 1 And Type 2
Distinct device preferences exist between individuals managing type 1 and type 2 diabetes in Argentina diabetes devices market. As of 2023, 71% of newly diagnosed type 1 patients reported using insulin pumps within the first nine months of diagnosis, a trend attributed to specialists' recommendations for stable glycemic control. Meanwhile, 58% of type 2 patients primarily depended on insulin pens, reflecting a preference for cost-effective and straightforward injection methods. According to one nationwide survey, 49% of type 1 patients found CGMs essential for reducing severe hypoglycemia episodes, while only 27% of type 2 respondents saw continuous monitoring as indispensable. Another important development: 35% of type 1 adolescents engaged in advanced sensor-augmented pump therapy, highlighting a growing appetite for integrated insulin delivery platforms.
Interestingly, public health clinics observed that 62% of type 1 individuals were open to technology upgrades every two years, contrasting with only 38% of type 2 users who shared the same willingness. In 2024, 44% of type 2 patients with complications (such as neuropathy) considered switching from pens to pumps upon their physicians' advice, showing a trend in the diabetes devices market. Research institutions in Mendoza found that 56% of type 1 participants experienced fewer diabetic ketoacidosis events with CGM-assisted therapy, whereas 19% of type 2 subjects noted better overall medication compliance after adopting simplified SMBG meters. Across multiple socioeconomic segments, 33% of type 1 patients integrated smartphone analytics with pump usage, a practice only 12% of type 2 patients embraced. This contrast underscores the divergent paths both groups take in optimizing device-based interventions.
Transformative Partnerships, Research, and Key Regulatory Pathways Shaping Future Market Directions
Industry collaboration and research breakthroughs form the backbone of Argentina's diabetes devices market evolution. In 2023, seven university-led clinical trials focused on artificial pancreas systems, with 37% showing promising results in reducing nocturnal hypoglycemia. The National Administration of Drugs, Foods, and Medical Devices expedited approvals for 41% of new diabetes device applications, accelerating market entry. Meanwhile, 26% of local biotech startups partnered with international firms to develop custom CGM solutions tailored to Argentina's population needs. Hospitals in Rosario reported a 53% rise in teleconsultations involving advanced insulin pump training, reflecting a nationwide push toward digitized care. Moreover, 15% of local medical device distributors introduced subscription-based models for sensor replacements, aiming to ease the financial burden on patients and encourage consistent usage.
Looking ahead, regulatory bodies have proposed a 2024 roadmap where 34% of government tenders include coverage for novel diabetes monitoring technologies, signaling expanded public-sector support. Parallelly, 22% of private insurance providers in the country's diabetes devices market unveiled premium reimbursement plans for integrated pump-CGM packages. Argentine research institutes are also forging global alliances; 29% of current diabetes collaborations involve foreign universities keen on data-driven problem-solving in the region's diverse patient base. Among device manufacturers, 63% have indicated that they plan to expand their product portfolios to address geriatric patient demands, underscoring the vast demographic reach in Argentina. Finally, 41% of medical conferences in 2024 are set to feature specialized tracks on diabetes device interoperability, reflecting an industry-wide commitment to bridging gaps and delivering seamless, patient-friendly technology solutions.
Request Free Customization of this report:
Triad Of Excellence: Abbott, Medtronic, Embecta Lead Argentina's Diabetes Devices Market With Collective Share of Over 45% Market Share
Abbott Laboratories, Medtronic Plc, and Embecta Corp. wield exceptional influence in Argentina's diabetes devices landscape, driven by robust R&D pipelines, localized strategic partnerships, and extensive distribution channels. As of 2023, these three leaders collectively supplied approximately 55% of advanced glucose monitoring and insulin delivery products, according to trade reports verified in early 2024. Much of this dominance stems from their long-standing collaborations with hospitals in Buenos Aires, Córdoba, and Rosario, where nearly 70% of diabetes patients receive specialized treatment. Medtronic's feature-rich insulin pumps, for instance, saw a 21% surge in adoption throughout 2023, credited to enhanced sensor-augmented technology and strong physician endorsement. Meanwhile, Embecta's pen solutions maintain a 14% year-over-year growth rate, driven by streamlined product training in public health clinics. This cohesive approach resonates with local healthcare providers, who prioritize device reliability, integration with telemedicine services, and comprehensive patient education initiatives above all else.
Abbott's leadership stands in the diabetes devices market out due to its FreeStyle Libre system, which more than 40% of continuous glucose monitoring (CGM) users in Argentina now rely on for round-the-clock glycemic insights. Updated regulatory filings from mid-2023 reveal Abbott's local manufacturing investments totaling USD 28 million, helping reduce import bottlenecks and ensure expedited device availability across multiple provinces. Medtronic distinguishes itself by partnering with 55% of Argentina's endocrinology-focused private practices, offering specialized training that shortens the learning curve for advanced insulin pump usage. Embecta has similarly carved a unique path through its robust post-purchase guidance, resulting in a reported 37% decrease in device-related patient complaints last year.
Argentina Diabetes Devices Market Key Players:
Abbott Laboratories B. Braun Ascensia Diabetes Care Holdings Becton, Dickinson and Company Convatec Group plc Dexcom Inc. F. Hoffmann-La Roche AG LifeScan IP Holdings, LLC Medtronic plc Novo Nordisk A/S Stevanato Group ViCentra B.V. Other prominent players
Key Segmentation:
By Type
Blood Glucose Meters and Strips Continuous Glucose Monitors (CGMs) Injection Pen Insulin Pumps Insulin Syringes Automated Insulin Delivery Systems Others
By Diabetes Type
Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Prediabetes
By Demography
Paediatric Adults Geriatric
By End User
Self & Homecare Hospitals & Clinics Diagnostic Centers Others
By Sales Channel
Hospital Pharmacies Retail Pharmacies Diabetes Clinics/Centers Online Pharmacies Others
Need a detailed report walkthrough? Request an online presentation from our analyst @
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
LinkedIn | Twitter | YouTube
CONTACT: Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
MENAFN01012025004107003653ID1109046570